Over the last few years, the strategy of performing fresh ET and supplement the luteal phase with very low doses of hCG has been used in our IVF unit, as an alternative to traditional CS, in the case of non-PCO patients with ovarian reserve markers and a wide ovarian reserve (AMH > 2.5 ng/mL, AFC > 15), who were expected to deliver a high response to COS without the very high OHSS risk typical of patients with PCOS. This evidence concerns the gene AMH and polycystic ovary syndrome.